Kizoo leads financing round in Reservoir Neuroscience to restore health to the aging brain
A first-in-kind compound reverses disease in blood vessels and repairs the damaged blood-brain barrier
Reservoir Neuroscience announced the completion of a $4M financing round to support the development of new therapies for age-related neurodegeneration. Reservoir will use the funds to develop its novel class of drug compounds designed to restore health to the brain’s blood vessels to rejuvenate the aging brain. The round was led by Kizoo Technology Capital, a leading rejuvenation biotech investor focused on startups reversing age-related damage at the cellular and molecular level, with additional participation from previous investors R42 Fund and Healthspan Ventures.
Reservoir’s unique approach to neurodegeneration was developed by co-founders Aaron Friedman and Vlad Senatorov, PhD neuroscientists from UC Berkeley who focus on understanding how aging blood vessels effects brain health. The company aims to develop the first drug that specifically targets vascular disease as a new way to restore brain health during natural aging and in age-related diseases. Emerging research has shown that a majority of the aging population develops vascular decline as early as middle age, making vascular pathology one of the first and most prevalent signs of brain disease. Using an innovative organ-on-chip technology to grow human blood vessels and study vascular aging, Reservoir discovered and developed a first-in-kind compound that reverses disease in blood vessels and repairs the damaged blood-brain barrier. Reservoir’s therapeutic strategy seeks to restore health to blood vessels to reverse degenerative damage that spreads from the blood vessels to the brain.
“By treating the underlying vascular problems that most people inevitably develop through aging, we are addressing the single greatest risk factor for developing neurodegenerative disease. We believe this approach to rejuvenating the aging brain will be effective not only as a single therapy, but also has broader potential for brain health and systemic benefits in a wide variety of age-related diseases”, says Dr. Friedman, CEO of Reservoir Neuroscience.
“We believe that Reservoir’s novel approach to restoring the health of the brain’s blood vessels, while also repairing the blood-brain barrier, has the potential to address the root causes of several neurological pathologies,” says Patrick Burgermeister, partner of Kizoo Technology Capital and new board member of Reservoir Neuroscience.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
